Sep 10 2019
Parkinson's disease is a progressive neurodegenerative disorder characterized by loss of dopaminergic neurons in the substantia nigra and striatum of brains. α-synuclein is the causative protein of Parkinson's disease. Ubiquitinated α-synuclein aggregates in nerve cells play a central role in the development of disease. A research team at Niigata University has discovered that G3BP1 protein inhibits ubiquitination and aggregation of α-synuclein. This study suggested that the G3BP1 plays a protective role in the development of Parkinson's disease by reducing α-synuclein ubiquitination and aggregation. Therefore, G3BP1 is a promising drug target for the treatment of Parkinson's disease.
Title: G3BP1 inhibits ubiquitinated protein aggregations induced by p62 and USP10
Journal: Scientific Reports
Authors: Sergei Anisimov, Masahiko Takahashi, Taichi Kakihana,Yoshinori Katsuragi, Hiroki Kitaura, Lu Zhang, Akiyoshi Kakita, Masahiro Fujii
Polygenic effects on the risk of Alzheimer's disease in the Japanese population
Trends in the incidence of renal replacement therapy due to rapidly progressive glomerulonephritis in Japan, 2006–2021
Uncovering The Cyclization Mechanism of Cyclic β-1,2-Glucan Synthase